# US 2013/0157948 A1 · Bispecific egfr/igfir binding molecules

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2013/0157948 A1
- Document ID: US20130157948A1
- Status: Published application
- Kind: A1
- Application number: 13/692,555
- Filed: 2012-12-03
- Published: 2013-06-20
- Earliest claimed: 2008-11-24
- Assignees: Bristol-Myers Squibb Company
- Inventors: Stuart EMANUEL; Linda ENGLE; Ray CAMPHAUSEN; Martin C. WRIGHT; Ginger CHAO; Marco GOTTARDIS; Joan CARBONI
- Web page: https://patentgrep.com/patent/US20130157948A1

## CPC

- C07K 14/78: Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
- A61K 38/39: Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
- A61K 39/3955: {against proteinaceous materials, e.g. enzymes, hormones, lymphokines}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 35/00: Antineoplastic agents
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07K 14/475: Growth factors; Growth regulators
- C07K 16/2863: {against receptors for growth factors, growth regulators}
- A61K 2039/505: {comprising antibodies}
- C07K 2317/31: multispecific
- C07K 2317/34: Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
- C07K 2317/92: Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C07K 2318/20: Antigen-binding scaffold molecules wherein the scaffold is not an immunoglobulin variable region or antibody mimetics
- C07K 2319/30: Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to bispecific molecules comprising an EGFR binding domain and a distinct IGFIR binding domain for use in diagnostic, research and therapeutic applications. The invention further relates to cells comprising such proteins, polynucleotide encoding such proteins or fragments thereof, and vectors comprising the polynucleotides encoding the innovative proteins. Exemplary bispecific molecules include antibody-like protein dimers based on the tenth fibronectin type III domain.

## Claims

### Claim 1

An antibody-like protein comprising a tenth fibronectin type III domain (10Fn3) that binds EGFR with a KD of less than 500 nM, wherein the EGFR binding 10Fn3 comprises a BC loop having the amino acid sequence set forth in amino acids 21-30 of SEQ ID NO: 112, a DE loop having the amino acid sequence set forth in amino acids 51-56 of SEQ ID NO: 112, and an FG loop having the amino acid sequence set forth in amino acids 76-92 of SEQ ID NO: 112.

### Claim 2

An antibody-like protein comprising a tenth fibronectin type III domain (10Fn3) that binds EGFR with a KD of less than 500 nM, wherein the EGFR binding 10Fn3 comprises a BC loop having the amino acid sequence XgWAPVDRYQXh (SEQ ID NO: 137), a DE loop having the amino acid sequence XiRDVYXj (SEQ ID NO: 138), and an FG loop having the amino acid sequence XkDYKPHADGPHTYHESXl(SEQ ID NO: 139); and wherein X is any amino acid and a, b, c, d, e, f, g, h, i, j, k, and l are integers independently selected from 0 to 5.

### Claim 3 (depends on 2)

The antibody-like protein of claim 2, wherein the EGFR binding 10Fn3 comprises a BC loop having the amino acid sequence SWWAPVDRYQ (SEQ ID NO: 115), a DE loop having the amino acid sequence PRDVYT (SEQ ID NO: 116), and an FG loop having the amino acid sequence TDYKPHADGPHTYHESP (SEQ ID NO: 117).

### Claim 4 (depends on 1)

The antibody-like protein of anyone of claim 1, further comprising a second tenth fibronectin type III domain (10Fn3).

### Claim 5 (depends on 4)

The antibody-like protein of claim 4, wherein the second 10Fn3 binds to IGF-IR.

### Claim 6 (depends on 4)

The antibody-like protein of claim 4, wherein the second 10Fn3 is covalently linked to the EGFR binding 10Fn3 via a polypeptide linker or a polyethylene glycol moiety.

### Claim 7

An antibody-like protein dimer comprising a tenth fibronectin type III domain (10Fn3) that binds IGF-IR with a KD of less than 500 nM covalently or non-covalently linked to a 10Fn3 that binds EGFR with a KD of less than 500 nM;
wherein the IGFIR binding 10Fn3 comprises a BC loop having the amino acid sequence XaSARLKVAXb (SEQ ID NO: 46), a DE loop having the amino acid sequence XcKNVYXd (SEQ ID NO: 48), and an FG loop having the amino acid sequence XeRFRDYQXf (SEQ ID NO: 50);
wherein the EGFR binding 10Fn3 comprises a BC loop having the amino acid sequence XgDSGRGSYQXh (SEQ ID NO: 40), a DE loop having the amino acid sequence XiGPVHXj (SEQ ID NO: 42), and an FG loop having the amino acid sequence XkDHKPHADGPHTYHEXl (SEQ ID NO: 44); and
wherein X is any amino acid and a, b, c, d, e, f, g, h, i, j, k, and l are integers independently selected from 0 to 5.

### Claim 8 (depends on 7)

The antibody-like protein dimer of claim 7,
wherein the IGF-IR binding 10Fn3 comprises a BC loop having the amino acid sequence SWSARLKVAR (SEQ ID NO: 45), a DE loop having the amino acid sequence PKNVYT (SEQ ID NO: 47), and an FG loop having the amino acid sequence TRFRDYQP (SEQ ID NO: 49); and an EGFR binding 10Fn3 comprising a BC loop having the amino acid sequence SWDSGRGSYQ (SEQ ID NO: 39), a DE loop having the amino acid sequence PGPVHT (SEQ ID NO: 41), and an FG loop having the amino acid sequence TDHKPHADGPHTYHESP (SEQ ID NO: 43).

### Claim 9 (depends on 7)

The antibody-like protein dimer of claim 7, wherein the IGF-IR binding 10Fn3 has an amino acid sequence at least 90% identical to SEQ ID NO: 3 and the EGFR binding 10Fn3 scaffold has an amino acid sequence at least 90% identical to SEQ ID NO: 5.

### Claim 10 (depends on 7)

The antibody-like protein dimer of claim 7, wherein the IGF-IR binding 10Fn3 is covalently linked to the EGFR binding 10Fn3 via a polypeptide linker or a polyethylene glycol moiety.

### Claim 11 (depends on 10)

The antibody-like protein dimer of claim 10, comprising an amino acid sequence at least 90% identical to SEQ ID NOs: 20, 21, 23, or 24.

### Claim 12

An antibody-like protein dimer comprising a tenth fibronectin type III domain (10Fn3) that binds IGF-IR with a KD of less than 500 nM covalently or non-covalently linked to a 10Fn3 that binds EGFR with a KD of less than 500 nM;
wherein the IGFIR binding 10Fn3 comprises a BC loop having the amino acid sequence XaSARLKVAXb (SEQ ID NO: 46), a DE loop having the amino acid sequence XcKNVYXd (SEQ ID NO: 48), and an FG loop having the amino acid sequence XeRFRDYQXf (SEQ ID NO: 50);
wherein the EGFR binding 10Fn3 comprises a BC loop having the amino acid sequence XmVAGAEDYQXn (SEQ ID NO: 34), a DE loop having the amino acid sequence XoHDLVXp (SEQ ID NO: 36), and an FG loop having the amino acid sequence XqDMMHVEYTEHXr (SEQ ID NO: 38); and
wherein X is any amino acid and a, b, c, d, e, f, m, n, o, p, q, and r are integers independently selected from 0 to 5.

### Claim 13 (depends on 12)

The antibody-like protein dimer of claim 12,
wherein the IGF-IR binding 10Fn3 comprises a BC loop having the amino acid sequence SWSARLKVAR (SEQ ID NO: 45), a DE loop having the amino acid sequence PKNVYT (SEQ ID NO: 47), and an FG loop having the amino acid sequence TRFRDYQP (SEQ ID NO: 49); covalently or non-covalently linked to an EGFR binding 10Fn3 comprising a BC loop having the amino acid sequence SWVAGAEDYQ (SEQ ID NO: 33), a DE loop having the amino acid sequence PHDLVT (SEQ ID NO: 35), and an FG loop having the amino acid sequence TDMMHVEYTEHP (SEQ ID NO: 37).

### Claim 14 (depends on 12)

The antibody-like protein dimer of claim 12, wherein the IGF-IR binding 10Fn3 has an amino acid sequence at least 90% identical to SEQ ID NO: 3 and the EGFR binding 10Fn3 has an amino acid sequence at least 90% identical to SEQ ID NO: 7.

### Claim 15 (depends on 12)

The antibody-like protein dimer of any one of claim 12, wherein the IGF-IR binding 10Fn3 scaffold is covalently linked to the EGFR binding 10Fn3 scaffold via a polypeptide linker or a polyethylene glycol moiety.

### Claim 16 (depends on 15)

The antibody-like protein dimer of claim 15, comprising an amino acid sequence at least 90% identical to SEQ ID NOs: 26, 27, 29, or 30.

### Claim 17

An antibody-like protein dimer comprising a tenth fibronectin type III domain (10Fn3) that binds IGF-IR with a KD of less than 500 nM covalently or non-covalently linked to a 10Fn3 that binds EGFR with a KD of less than 500 nM;
wherein the IGFIR binding 10Fn3 comprises a BC loop having the amino acid sequence XaSARLKVAXb (SEQ ID NO: 46), a DE loop having the amino acid sequence XcKNVYXd (SEQ ID NO: 48), and an FG loop having the amino acid sequence XeRFRDYQXf (SEQ ID NO: 50);
wherein the EGFR binding 10Fn3 comprises a BC loop having the amino acid sequence XsLPGKLRYQXt (SEQ ID NO: 60), a DE loop having the amino acid sequence XuHDLRXw (SEQ ID NO: 62), and an FG loop having the amino acid sequence XyNMMHVEYSEYXz (SEQ ID NO: 64); and
wherein X is any amino acid and a, b, c, d, e, f, s, t, u, w, y and z are integers independently selected from 0 to 5.

### Claim 18 (depends on 17)

The antibody-like protein dimer of claim 17,
wherein the IGF-IR binding 10Fn3 comprises a BC loop having the amino acid sequence SWSARLKVAR (SEQ ID NO: 45), a DE loop having the amino acid sequence PKNVYT (SEQ ID NO: 47), and an FG loop having the amino acid sequence TRFRDYQP (SEQ ID NO: 49); covalently or non-covalently linked to an EGFR binding 10Fn3 comprising a BC loop having the amino acid sequence LPGKLRYQ (residues 3-13 of SEQ ID NO: 59), a DE loop having the amino acid sequence PHDLR (residues 1-5 of SEQ ID NO: 61), and an FG loop having the amino acid sequence TNMMHVEYSEY (residues 1-11 of SEQ ID NO: 63).

### Claim 19 (depends on 17)

The antibody-like protein dimer of claim 17, wherein the IGF-IR binding 10Fn3 has an amino acid sequence at least 90% identical to SEQ ID NO: 3 and the EGFR binding 10Fn3 has an amino acid sequence at least 90% identical to SEQ ID NO: 82.

### Claim 20 (depends on 17)

The antibody-like protein dimer of claim 17, wherein the IGF-IR binding 10Fn3 scaffold is covalently linked to the EGFR binding 10Fn3 scaffold via a polypeptide linker or a polyethylene glycol moiety.

### Claim 21 (depends on 20)

The antibody-like protein dimer of claim 20, comprising an amino acid sequence at least 90% identical to any one of SEQ ID NOs: 53, 54, 87, 88, 98, 99, 104 or 105.

### Claim 22

An antibody-like protein dimer comprising a tenth fibronectin type III domain (10Fn3) that binds IGF-IR with a KD of less than 500 nM covalently or non-covalently linked to a 10Fn3 that binds EGFR with a KD of less than 500 nM;
wherein the IGFIR binding 10Fn3 comprises a BC loop having the amino acid sequence XaSARLKVAXb (SEQ ID NO: 46), a DE loop having the amino acid sequence XcKNVYXd (SEQ ID NO: 48), and an FG loop having the amino acid sequence XeRFRDYQXf (SEQ ID NO: 50);
wherein the EGFR binding 10Fn3 comprises a BC loop having the amino acid sequence XgHERDGSRQXh (SEQ ID NO: 134), a DE loop having the amino acid sequence XiGGVRXj (SEQ ID NO: 135), and an FG loop having the amino acid sequence XkDYFNPTTHEYIYQTTXl (SEQ ID NO: 136); and
wherein X is any amino acid and a, b, c, d, e, f, g, h, i, j, k and l are integers independently selected from 0 to 5.

### Claim 23 (depends on 22)

The antibody-like protein dimer of claim 22,
wherein the IGF-IR binding 10Fn3 comprises a BC loop having the amino acid sequence SWSARLKVAR (SEQ ID NO: 45), a DE loop having the amino acid sequence PKNVYT (SEQ ID NO: 47), and an FG loop having the amino acid sequence TRFRDYQP (SEQ ID NO: 49); covalently or non-covalently linked to an EGFR binding 10Fn3 comprising a BC loop having the amino acid sequence SWHERDGSRQ (SEQ ID NO: 109), a DE loop having the amino acid sequence PGGVRT (SEQ ID NO: 110), and an FG loop having the amino acid sequence TDYFNPTTHEYIYQTTP (SEQ ID NO: 111).

### Claim 24 (depends on 22)

The antibody-like protein dimer of claim 22, wherein the IGF-IR binding 10Fn3 has an amino acid sequence at least 90% identical to SEQ ID NO: 3 and the EGFR binding 10Fn3 has an amino acid sequence at least 90% identical to SEQ ID NO: 107.

### Claim 25 (depends on 22)

The antibody-like protein dimer claim 22, wherein the IGF-IR binding 10Fn3 scaffold is covalently linked to the EGFR binding 10Fn3 scaffold via a polypeptide linker or a polyethylene glycol moiety.

### Claim 26 (depends on 25)

The antibody-like protein dimer of claim 25, comprising an amino acid sequence at least 90% identical to any one of SEQ ID NOs: 118-125.

### Claim 27 (depends on 1)

A pharmaceutically acceptable composition comprising the antibody-like protein dimer or antibody-like protein of claim 1, wherein the composition is essentially pyrogen free.

### Claim 28 (depends on 27)

A method for treating a hyperproliferative disorder in a subject comprising administering to a subject in need thereof a therapeutically effective amount of the composition of claim 27.

### Claim 29

An antibody-like protein comprising a tenth fibronectin type III domain (10Fn3) that binds EGFR with a KD of less than 500 nM, wherein the EGFR binding 10Fn3 comprises a BC loop comprising the amino acid sequence XXXXXXYQ, a DE loop comprising the amino acid sequence XX(V/I/L/M/A)X, and an FG loop comprising the amino acid sequence (D/N)Xn, wherein X is any amino acid and n is 9-14 amino acids.

### Claim 30 (depends on 29)

The antibody-like protein of claim 29, wherein n is 14.

### Claim 31 (depends on 29)

The antibody-like protein of claim 29, further comprising a second tenth fibronectin type III domain (10Fn3).

### Claim 32 (depends on 31)

The antibody-like protein of claim 31, wherein the second 10Fn3 binds to IGF-IR.

### Claim 33 (depends on 31)

The antibody-like protein of claim 31, wherein the second 10Fn3 is covalently linked to the EGFR binding 10Fn3 via a polypeptide linker or a polyethylene glycol moiety.

### Claim 34 (depends on 29)

A pharmaceutically acceptable composition comprising the antibody-like protein of any one of claim 29, wherein the composition is essentially pyrogen free.

### Claim 35 (depends on 34)

A method for treating a hyperproliferative disorder in a subject comprising administering to a subject in need thereof a therapeutically effective amount of the composition of claim 34.
